Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor–β1‐mediated regulatory abnormalities including up‐regulation of C‐Myc and MTA1
Kidd M, Modlin IM, Pfragner R, Eick GN, Champaneria MC, Chan AK, Camp RL, Mane SM. Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor–β1‐mediated regulatory abnormalities including up‐regulation of C‐Myc and MTA1. Cancer 2007, 109: 2420-2431. PMID: 17469181, DOI: 10.1002/cncr.22725.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternCadherinsCarcinoid TumorCell ProliferationCells, CulturedCyclin-Dependent Kinase Inhibitor p21Enterochromaffin CellsGene Expression Regulation, NeoplasticHistone DeacetylasesHumansIntestinal NeoplasmsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3PhosphorylationProto-Oncogene Proteins c-mycRepressor ProteinsSignal TransductionSmad ProteinsTrans-ActivatorsTransforming Growth Factor beta1Tumor Cells, CulturedUp-RegulationConceptsEffects of TGFbeta1Normal EC cellsC-MycDownstream targetsEC cellsSmad2 phosphorylationE-cadherinCell proliferationEC cell proliferationProtein expressionGrowth regulatory mechanismsCandidate downstream targetsTranscriptional networksC-Myc pathwayC-myc transcriptsGrowth promotionCytostatic programGene responsesEC cell linesRegulatory mechanismsTranscript expressionTranscriptsNuclear translocationTumor cellsMTA1The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. Journal Of Translational Medicine 2007, 5: 6. PMID: 17257402, PMCID: PMC1796544, DOI: 10.1186/1479-5876-5-6.Peer-Reviewed Original ResearchConceptsMetastatic melanomaXIAP expressionCell linesCy5-conjugated antibodiesMechanism of actionMelanoma cell linesPrimary lesionOvarian cancerTherapeutic approachesTissue microarrayDisease aggressionCarboplatin sensitivityChemotherapy resistanceMalignant progressionClinical specimensBenign counterpartsCarboplatinMelanomaChemotherapy sensitizationPrimary specimensPhenoxodiolResistant cellsMelanoma cellsHigh expressionMelanoma resistance